Regulatory T cells and multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 8, Issue 5, 2008, Pages 283-286

  Joshua, Douglas E ^a,b   Brown, Ross D ^a   Ho, P Joy ^a,b   Gibson, John ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

FoxP3; Host tumor interactions; Monoclonal gammopathy of unknown significance; Trogocytosis

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELPHALAN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CANCER INFILTRATION; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMOLYSIS; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; LYMPHOCYTE FUNCTION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY; ANIMAL; GENETICS; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSURVEILLANCE; METABOLISM; PARACRINE SIGNALING; PATHOLOGY;

ANIMALS; B-LYMPHOCYTES; FORKHEAD TRANSCRIPTION FACTORS; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; IMMUNITY; IMMUNOLOGIC FACTORS; IMMUNOLOGIC SURVEILLANCE; MULTIPLE MYELOMA; PARACRINE COMMUNICATION; T-LYMPHOCYTES, REGULATORY;

EID: 58149327333     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.039     Document Type: Review

References (45)

1. Sakaguchi S. Regulatory T cells: key controllers of immunologic selftolerance. Cell 2000; 101:455-8.
2. Shevach EM. Regulatory T Cells in autoimmunity. Annu Rev Immunol 2000; 18:423-49.
3. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3:253-7.
4. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6:331-7.
5. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192:303-10.
6. McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16:311-23.
7. Szanya V, Ermann J, Taylor C, et al. The subpopulation of CD4+ CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002; 169:2461-5.
8. Takeda I, Ine S, Killeen N, et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 2004; 172:3580-9.
9. Caramalho I, Lopes-Carvalho T, Ostler D, et al. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197:403-11.
10. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20-1.
11. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/ winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27:68-73.
12. Liu W, Putnam Al, Xu-Yu Z, et al. CD127 expression inversely corre-lates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203:1701-11.
13. Valzasina B, Piconese S, Guiducci C, et al. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25-lymphocytes is thymus and proliferation independent. Cancer Res 2006; 66:4488-95.
14. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003; 81:331-71.
15. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells--they're back and critical for regulation of autoimmunity! Immunol 2001; 182:149-63.
16. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3- positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108:1291-7.
17. Bettelli E, Carrier Y, Gao W, et al. Reciprocal development pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8.
18. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006; 107:301-4.
19. Banerjee DK, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006; 108:2655-61.
20. Hansson L, Abdalla AO, Moshfegh A, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 2007; 13:1503-10.
21. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183:725-9.
22. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2:227-38.
23. Bourgeois C, Veiga-Fernandes H, Joret AM, et al. CD8 lethargy in the absence of CD4 help. Eur J Immunol 2002; 32:2199-207.
24. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307.
25. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vito administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59:3128-33.
26. Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating FoxP3+CD25+Cd4+ regulatory T cells. J Exp Med 2005; 202:885-91.
27. Chaput N, Darrasse-Jèze G, Bergot AS, et al. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol 2007; 179:4969-78.
28. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
29. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766-72.
30. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9:4404-8.
31. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-61.
32. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103:1755-62.
33. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018-25.
34. LeMaoult J, Caumartin J, Carolsella ED. Exchanges of membrane patches (trogocytosis) split theoretical and actual functions of immune cells. Hum Immunol 2007; 68:240-3.
35. Brown R, Murray A, Pope B, et al. B7+ T cells in myeloma: an acquired marker of prior chronic antigen presentation. Leuk Lymphoma 2004; 45:363-71.
36. Feger U, Tolosa E, Huang Y, et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood 2007; 110:568-77.
37. Wiendl H. Fast track to becoming a regulatory T cell: "trogocytosis" of immune-tolerogenic HLA-G. Blood 2007; 109:1796-7.
38. Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of naive CD4+CD25 high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107:3940-9.
39. Atanackovic D, Cao Y, Luetkens T, et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008; 93:423-30.
40. Porrata LF, Gertz MA, Geyer SM, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004; 18:1085-92.
41. Condomines M, Quittet P, Lu ZY, et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with a high-dose cyclophosphamide and granulocyte colony-stimulating factor [published erratum appears in: J Immunol 2006; 177:5748]. J Immunol 2006; 176:6631-9.
42. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus- host disease after bone marrow transplantation. Nat Med 2003; 9:1144-50.
43. Klebanoff CA, Khong HT, Antony PA, et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T-cell mediated tumor immunotherapy [published erratum appears in: Trends Immunol 2005; 26:298]. Trends Immunol 2005; 26:111-7.
44. Sze DM, Giesajtis G, Brown RD, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-)compartment. Blood 2001; 98:2817-27.
45. Curiel T. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167-74.